Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
GLP-1 medications have been around since about 2005, just fyi. Though it’s only recently they have been marketed for general weight management.